AUTL

In a report released today, Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target of $13.00. The company's shares closed last Monday at $2.28, close to its 52-week low of $2.20. According to TipRanks.com, Blum is ranked 0 out of 5 stars with an average return of -36.2% and a 18.6% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics. Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $14.00, a 444.7% upside from current levels.
https://www.tipranks.com/news/blurbs/needham-thinks-autolus-therapeutics-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral